ADC “Biological Missile” Production Code Series V | Drug Substance Bulk Filling Paired with Sterile Filling Bags, Guarding the Last Mile of ADC Commercial Production

ADC drugs, with their core advantages of precise targeting and high anti-tumor efficacy, have firmly secured their place in the golden track of biomedicine. As industry production capacity continues to expand, 10,000-liter reaction systems and 1,000-liter drug substance processing have become the norm for mass production.

Compared to conventional biologics, ADC production has stricter quality control, higher material value, and a greater cost for contamination risks. Among them, drug substance bulk filling and drug product filling, as the two core processes at the end of mass production, directly determine batch stability, product safety, and production costs, making them critical links for ADC commercialization.

Figure 1: BioLink Single-use ADC Bioprocess Platform

The end-stage ADC process is divided into two major interconnected phases: precise drug substance bulk filling completes the sterile aliquoting and low-temperature storage of the purified drug substance, avoiding cross-contamination and providing qualified raw materials for subsequent formulation processes; sterile drug product filling relies on high-cleanliness consumables to complete the final shaping of the drug solution, serving as the last quality checkpoint before the drug is launched. These two processes are seamlessly connected to jointly bridge the last mile of ADC mass production.

Say Goodbye to Manual Shortcomings!

Fully Automated Bulk Filling Solves the Pain Points of Drug Substance Mass Production

Currently, most pharmaceutical companies use manual bulk filling during the pilot stage, but this model is completely incompatible with large-scale mass production: poor bulk filling precision, large batch variations, and high contamination risks from manual intervention, along with incomplete data traceability and difficult auditing, make it hard to match the increasingly strict requirements of pharmaceutical regulations.

Many enterprises have a cognitive misunderstanding: small-volume drug substances do not require automated equipment, and manual operation saves money. However, from a long-term mass production perspective, material loss, compliance risks, capacity constraints, and rising labor costs caused by manual operations will actually significantly increase comprehensive operating costs, and the process cannot be linearly scaled up.

Addressing industry pain points, BioLink, after two years of refinement, repeated debugging, and iteration with industry experts, has launched the BioHub^®Fill Single-use Bulk Filling System, providing a fully automated, unattended, high-precision standardized bulk filling solution with full traceability for compliance for ADC drug substance mass production.

Figure 2: BioHub®Fill Single-use Bulk Filling System

Integrated Software and Hardware Solution:

Customized Bulk Filling Consumables + Professional Equipment Hardware

The core of sterile and precise bulk filling lies in the high adaptability between equipment and consumables. Relying on its self-developed and self-produced end-to-end capabilities, BioLink has achieved the integrated design and integrated validation of equipment hardware and single-use bulk filling consumables, ensuring a stable and sterile process from the source of the flow path.

01 Customized single-use bulk filling consumables, adapting to ADC drug substance processes

Core pipelines customized on demand, with low-loss design to preserve activity

It uses high-purity specialized tubing with a smooth inner wall and low protein adsorption rate, maximizing the retention of ADC drug substance activity; multi-channel manifolds can be customized according to mass production needs to complete multi-container bulk filling synchronously, improving mass production efficiency. Integrated customized capsule sterile filters adapt to drug substance clarity and flow rate requirements, achieving synchronous sterile filtration during bulk filling. Paired with sterile connectors and sterile aseptic disconnectors, the entire process operates in a closed manner without open exposure, thoroughly avoiding external contamination and liquid leakage problems.

Adaptable auxiliary consumables, fully controllable throughout the process

Auxiliary consumables such as pressure sensors use USP Class VI high-quality materials, accurately linking with equipment monitoring and alarm logic to stably monitor pipeline pressure differences in real-time; matching sterile connection and disconnection components adapt to large-batch continuous sterile production.

02 Core advantages of fully automated bulk filling equipment, empowering large-scale mass production

Ultra-high bulk filling precision, highly consistent batches

Equipped with a smart PID weighing calibration algorithm, the bulk filling precision achieves ±0.6%, adaptable to multiple types of fluids such as ADC drug substances; it supports fully automatic unattended operation, breaking free from manual repeated calibration and ensuring mass production batch stability.

Flexible hardware structure, adaptable to multi-scenario production

The bracket can be flexibly adjusted, compatible with multi-specification freezing bottles and freezing bags; combined with high-precision bubble detection and low-residue flow path design, it effectively recovers high-value drug substances and reduces material loss.

Full-process pressure linkage monitoring, more stable production

Pump operation parameters and pressure sensing data are linked in real-time, automatically stopping and alarming upon anomalies, effectively avoiding the risks of highly active liquid overflow and pipeline breakage, ensuring mass production safety.

Complete audit traceability, easily passing compliance audits

It records core data such as weight, time, pressure, and operation logs throughout the entire process, supports electronic signatures and data audit trails, complies with FDA 21 CFR Part 11 regulations, and can connect with enterprise SCADA and MES systems to meet pharmaceutical regulatory inspection requirements.

Customized Sterile Filling Bags, Guarding the Ultimate Defense Line of Drug Product Filling

After the completion of drug substance bulk filling and low-temperature storage, the drug solution will enter the back-end drug product filling process. As the last process before market launch, the filling stage has strict requirements for the cleanliness, airtightness, and low-residue properties of consumables, which directly determine the finished product quality and material utilization rate.

BioLink's exclusive single-use sterile filling bags seamlessly connect with the front-end bulk filling process, escorting ADC drug product filling mass production with the advantages of high cleanliness, high adaptability, and low loss.

01 B+A high-cleanliness production, strictly controlling particulate contamination

The filling bags complete bag making, assembly, and packaging entirely within a Grade B background with Grade A (ISO 5) environment. Compared to traditional Grade C production environments, it can significantly reduce particulates and visible foreign matter residues. Test data shows that its 10μm particulate level is significantly better than industry standards, adapting to the strict production requirements of ADC sterile preparations.

02 100% full-item integrity testing, zero leakage guarantee

After assembly, every set of filling bags passes a 100% integrity test. Paired with a self-developed high-precision tester, it can detect micron-level defects, completely eliminating the risks of leakage and contamination during storage and filling.

03 Full-dimensional customization, matching personalized processes

Filtration schemes, tubing, and filling needle specifications can be customized based on drug batch capacity and filling parameters, compatible with multi-brand equipment, and seamlessly adaptable to the existing production lines of various enterprises.

04 Ultra-low hold-up volume design, significantly reducing mass production loss

Through refined designs such as boat-shaped connector matching, multi-angle inclined bag body structure, and adapting the number of filling needles, it minimizes drug solution residue to the greatest extent, efficiently recovers high-value ADC drug solution, and significantly lowers mass production costs.

Figure 3: BioHub^® Single-use Filling System

Front and Rear End Process Synergy, Creating a Complete Solution for ADC Mass Production

BioLink's BioHub®Fill Automated Bulk Filling System (drug substance bulk filling software and hardware) + customized sterile filling bags (drug product filling consumables) form a front-to-back connected, fully closed-loop end-stage ADC mass production solution: the front-end automated bulk filling solves the pain points of low efficiency, poor precision, difficult compliance, and high risks in drug substance mass production; the back-end customized filling bags guard the bottom line of sterile, low-loss, and stable quality for drug products.

Based on customers' actual mass production needs, the entire solution discards homogenized designs and balances process adaptability, regulatory compliance, and mass production economy. It can provide a one-stop fluid process solution from compounding, filtration, liquid storage, and bulk filling to filling, comprehensively adapting to ADC large-scale and commercial production.

Under the industry trends of capacity upgrading and tightening regulations, a standardized, automated, and traceable fluid process system has become the core competitiveness for ADC enterprises to improve quality, increase efficiency, and achieve stable commercialization.

Conclusion

BioLink, with deep expertise in biopharmaceutical fluid processing, provides customized products and end-to-end services to help clients tackle ADC production challenges and accelerate the high-quality industrialization of advanced biologics.